Roser Belmonte1,2,3, Monique Messaggi-Sartor4,5, Montse Ferrer6,5,7, Angels Pont5, Ferran Escalada4,6,5. 1. Hospital Mar-Esperança, Parc de Salut Mar, Sant Josep de la Muntanya, 12, 08024, Barcelona, Spain. Roserbelmonte59@gmail.com. 2. Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain. Roserbelmonte59@gmail.com. 3. IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain. Roserbelmonte59@gmail.com. 4. Hospital Mar-Esperança, Parc de Salut Mar, Sant Josep de la Muntanya, 12, 08024, Barcelona, Spain. 5. IMIM (Hospital del Mar Medical Research Institute), Doctor Aiguader 88, 08003, Barcelona, Spain. 6. Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain. 7. CIBER en Epidemiología y Salud Pública, CIBERESP, Madrid, Spain.
Abstract
OBJECTIVE: Determine the changes in shoulder strength, shoulder range of motion, and arm volume in breast cancer patients treated with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) METHOD: Sixty-eight SLNB and 44 ALND patients were followed up from pre-surgery to 5 years after surgery. Primary outcomes were the differences between affected and non-affected sides for the following: shoulder strength measured by dynamometry, shoulder range of motion measured by goniometry, and lymphedema measured by volume. As a secondary outcome, health-related quality of life (HRQL) was assessed by the Short Form-36 Health Survey (SF-36) and the Functional Assessment of Cancer Therapy for breast cancer (FACT-B+4) questionnaires. Changes over time were tested for SLNB and ALND using univariate repeated measures analysis of variance. Generalized estimating equation models were constructed to assess the effect of SLNB and ALND over time. RESULTS: After 5 years, the ALND group had significant loss of strength for internal rotators (1.39 kg, p = 0.001) and significant arm volume increase (132.45 mL, p = 0.031). The ALND group had a greater number of patients with clinically relevant internal rotator strength loss (38.7 vs. 13.6%, p = 0.012) and a greater number of lymphedema requiring treatment (33.3 vs. 3.4%, p < 0.001) than the SLNB group. A loss of strength for shoulder external rotators, shoulder range of motion, and HRQL in physical and arm domains persisted at 5 years in both SLNB and ALND groups. CONCLUSION: These results could help understand and plan the prevention, needs, and long-term care of breast cancer patients.
OBJECTIVE: Determine the changes in shoulder strength, shoulder range of motion, and arm volume in breast cancerpatients treated with sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) METHOD: Sixty-eight SLNB and 44 ALNDpatients were followed up from pre-surgery to 5 years after surgery. Primary outcomes were the differences between affected and non-affected sides for the following: shoulder strength measured by dynamometry, shoulder range of motion measured by goniometry, and lymphedema measured by volume. As a secondary outcome, health-related quality of life (HRQL) was assessed by the Short Form-36 Health Survey (SF-36) and the Functional Assessment of Cancer Therapy for breast cancer (FACT-B+4) questionnaires. Changes over time were tested for SLNB and ALND using univariate repeated measures analysis of variance. Generalized estimating equation models were constructed to assess the effect of SLNB and ALND over time. RESULTS: After 5 years, the ALND group had significant loss of strength for internal rotators (1.39 kg, p = 0.001) and significant arm volume increase (132.45 mL, p = 0.031). The ALND group had a greater number of patients with clinically relevant internal rotator strength loss (38.7 vs. 13.6%, p = 0.012) and a greater number of lymphedema requiring treatment (33.3 vs. 3.4%, p < 0.001) than the SLNB group. A loss of strength for shoulder external rotators, shoulder range of motion, and HRQL in physical and arm domains persisted at 5 years in both SLNB and ALND groups. CONCLUSION: These results could help understand and plan the prevention, needs, and long-term care of breast cancerpatients.
Entities:
Keywords:
Breast cancer; Lymphedema; Quality of life; Shoulder
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: J S Rietman; J H B Geertzen; H J Hoekstra; P Baas; W V Dolsma; J de Vries; J W Groothoff; W H Eisma; P U Dijkstra Journal: Eur J Surg Oncol Date: 2006-01-04 Impact factor: 4.424
Authors: Teresa S Lee; Sharon L Kilbreath; Kathryn M Refshauge; Robert D Herbert; Jane M Beith Journal: Breast Cancer Res Treat Date: 2007-09-26 Impact factor: 4.872
Authors: Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee Journal: J Clin Oncol Date: 2008-10-06 Impact factor: 44.544
Authors: María Nieves Muñoz-Alcaraz; Antonio José Jiménez-Vílchez; Mirian Santamaría-Peláez; Luis A Pérula-de Torres; María Victoria Olmo-Carmona; María Teresa Muñoz-García; Presentación Jorge-Gutiérrez; Jesús Serrano-Merino; Esperanza Romero-Rodríguez; Lorena Rodríguez-Elena; Raquel Refusta-Ainaga; María Pilar Lahoz-Sánchez; Belén Miró-Palacios; Mayra Medrano-Cid; Rosa Magallón-Botaya; Luis A Mínguez-Mínguez; Josefa González-Santos; Jerónimo J González-Bernal Journal: J Clin Med Date: 2022-04-16 Impact factor: 4.964
Authors: Stéphane Vignes; Pascal Fau-Prudhomot; Laura Simon; Marie-Laure Sanchez-Bréchot; Maria Arrault; Fabrice Locher Journal: Support Care Cancer Date: 2019-04-13 Impact factor: 3.603
Authors: Paula Gala-Alarcón; Virginia Prieto-Gómez; Javier Bailón-Cerezo; María José Yuste-Sánchez; Beatriz Arranz-Martín; María Torres-Lacomba Journal: Sci Rep Date: 2021-11-26 Impact factor: 4.379
Authors: Electra D Paskett; Jennifer Le-Rademacher; Jill M Oliveri; Heshan Liu; Drew K Seisler; Jeffrey A Sloan; Jane M Armer; Michelle J Naughton; Karen Hock; Michael Schwartz; Gary Unzeitig; Marianne Melnik; Lisa D Yee; Gini F Fleming; John R Taylor; Charles Loprinzi Journal: Cancer Date: 2020-10-20 Impact factor: 6.860